Akero Therapeutics, Inc.

NASDAQ:AKRO

44.15 (USD) • At close March 14, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q4
Revenue 00000.284000000000000000000000000
Cost of Revenue 000.0010.0010.0020.0050.0690.0680.0650.0660.0650.0640.0630.060.060.0610000000000000
Gross Profit 00-0.001-0.0010.282-0.005-0.069-0.068-0.065-0.066-0.065-0.064-0.063-0.06-0.06-0.0610000000000000
Gross Profit Ratio 00000.993000000000000000000000000
Reseach & Development Expenses 69.29372.23255.32250.6553.39238.63427.98521.78718.3225.08721.36320.51427.71119.4723.97610.60225.70917.37913.0378.79113.13813.8855.964.0631.9831.2538.420.2260.68
General & Administrative Expenses 8.7329.47110.4199.3048.4817.9817.6446.9667.111.0046.2315.5374.7284.8834.994.5264.0744.1593.4173.5883.0832.4241.6491.4490.9850.4740.2420.1950.28
Selling & Marketing Expenses 00-0.001-0.001-0.002000000000000000000000000
SG&A 8.7329.47110.4189.3038.4797.9817.6446.9667.111.0046.2315.5374.7284.8834.994.5264.0744.1593.4173.5883.0832.4241.6491.4490.9850.4740.2420.1950.28
Other Expenses 00-10.4180-16.6267.8445.4033.3792.7230.8730.24400.0150.0230.0330.0380.0720.1350.2470.4930.610.7550.3810.15-58.504-9.421-0.01100
Operating Expenses 78.02581.70365.7459.95361.87146.61535.62928.75325.4236.09127.59426.05132.43924.35328.96615.12829.78321.53816.45412.37916.22116.3097.6095.5122.9681.7278.6620.4210.96
Operating Income -78.025-81.703-65.741-59.954-61.873-46.615-35.629-28.753-25.42-36.091-27.594-26.051-32.439-24.353-28.966-15.128-29.783-21.538-16.454-12.379-16.221-16.309-7.609-5.512-2.968-1.727-8.662-0.421-0.96
Operating Income Ratio 0000-217.863000000000000000000000000
Total Other Income Expenses Net 8.0018.9989.7546.616.6876.9564.5462.9222.3610.5490.1910.0220.0150.0230.0330.0380.0720.1350.2470.4930.610.7550.3810.15-58.504-9.421-0.01100
Income Before Tax -70.024-72.705-55.987-53.344-55.186-39.659-31.083-25.831-23.059-35.542-27.403-26.029-32.424-24.33-28.933-15.09-29.711-21.403-16.207-11.886-15.611-15.554-7.228-5.362-61.472-11.148-8.673-0.421-0.96
Income Before Tax Ratio 0000-194.317000000000000000000000000
Income Tax Expense 000-0.042-12.5278.7326.26-2.465-2.574-0.5490.297-0.022-0.011-0.051-0.05-0.05-0.011-0.006-1.323-1.237-0.046-16.309-7.609-5.362-2.9680-8.662-0.4210
Net Income -70.024-72.705-55.987-53.344-55.186-39.659-31.083-23.366-20.485-34.993-27.403-26.007-32.424-24.33-28.933-15.09-29.711-21.403-16.207-11.886-15.611-15.554-7.228-5.362-61.472-11.148-8.673-0.421-1.026
Net Income Ratio 0000-194.317000000000000000000000000
EPS -0.99-1.05-0.81-0.9-0.99-0.71-0.6-0.5-0.44-0.91-0.77-0.74-0.93-0.7-0.83-0.43-0.86-0.63-0.57-0.42-0.55-0.56-2.21-0.2-2.9-0.53-0.41-0.02-4.54
EPS Diluted -0.99-1.05-0.81-0.9-0.99-0.71-0.6-0.5-0.44-0.91-0.77-0.74-0.93-0.7-0.83-0.43-0.86-0.63-0.57-0.42-0.55-0.56-2.21-0.2-2.9-0.53-0.41-0.02-4.53
EBITDA -68.809-71.458-54.755-52.352-54.287-38.766-30.157-25.306-22.632-35.152-27.285-25.965-32.428-24.27-28.873-15.117-29.772-21.538-16.454-12.379-16.221-16.309-7.6090.15-2.968-11.148-0.081-0.421-0.066
EBITDA Ratio 0000-217.856000000000000000000000000